Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02328664
Other study ID # SCAPURA-Study
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date August 2015
Est. completion date May 2019

Study information

Verified date December 2019
Source Deventer Ziekenhuis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

After endoscopic removal of a colorectal polyp that harbors (unexpected) adenocarcinoma, pathology usually can not guarantee a radical resection from an oncological point of view. In such case, additional surgical resection is advised. However, only in 15% of patients, residual adenocarcinoma is found. This study investigates the sensitivity of biopsies from the polypectomy scar for residual adenocarcinoma.


Description:

Rationale: colorectal polyps may harbor adenocarcinoma. Numbers are increasing due to the nationwide colorectal screening program. After endoscopic removal, rescue surgery is often performed because radicality can not be guaranteed by the pathologist. However, in 85% of surgical specimen no residual malignancy is found. Given morbidity and mortality associated with surgery a method to diagnose residual cancer is needed.

Biopsies from the polypectomy site are variably used to reduce the likelihood of residual tumor at the polypectomy site under these circumstances. However, the sensitivity of such biopsies is unknown.

Objective: to evaluate the sensitivity of second-look endoscopic biopsies from the polypectomy site for residual tumor.

Study design: prospective cross-sectional design using a multi-center approach. Study population: patients planned for rescue surgery for the sole reason of (potentially) irradical endoscopic resection of a colorectal adenocarcinoma without poor differentiation, lymphovascular invasion or tumor budding and without other signs of dissemination.

Intervention: endoscopic biopsies from the polypectomy site before operation. Main study parameters/endpoints: sensitivity of second-look biopsies from the polypectomy site for residual tumor in the resected bowel and postoperative mortality. Various other factors will be assessed that might be associated with residual cancer.

Nature and extent of the burden and risks associated with participation and benefit: Depending on the situation: a): In case a tattoo needs to be done of the polypectomy site, a second endoscopy is done anyway and taking biopsies (painless) will be of no extra burden; b): In case no tattoo needs to be done a sigmoidoscopy (lesion distal to the splenic flexure) or colonoscopy (proximal to the splenic flexure) needs to be arranged for the purpose of this study. A sigmoidoscopy takes 10-20 minutes. Preparation consists of two enemas. A colonoscopy takes 20-30 minutes. Preparation consists of drinking 3 litre of MoviPrep®, both usually doe at home. Notice that the patient has recent experience with colonoscopy. If necessary, both investigations can be arranged under conscious sedation (the rule in colonoscopy), which also implies day-care admission. The risk of complications of a second endoscopy is estimated < 1:5000. The benefit of a 2nd colonoscopy is the discovery of new polyps in 10-25% of cases.


Recruitment information / eligibility

Status Terminated
Enrollment 246
Est. completion date May 2019
Est. primary completion date May 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Aged 18 or above.

- Endoscopically removed colorectal lesion with the following pathological characteristics:

- A moderately-to-well differentiated adenocarcinoma.

- If possible to judge: distance between adenocarcinoma and vertical or lateral resection margin is less than 1 mm.

- In case of piecemeal resection: unjudgeable radicality (mostly due to loss of orientation and multiple fragments).

- Absence of / unjudgeable lymphatic / vascular invasion.

- No or only grade I tumor budding.

- No suspicion of dissemination on the following investigations: serum carcino-embryonic antigen, a computer tomographic (CT) scan of the abdomen and a chest X-ray; in case of a rectal tumor (less than 15 cm from the anal verge): an additional magnetic resonance imaging of the rectum.

- Operation is advised in agreement with the Dutch Guideline on Colorectal cancer, planned and agreed on by the patient.

- Written informed consent is obtained.

Exclusion Criteria:

- Pathology shows one or more of the following characteristics:

- A radical en-bloc resection with a free vertical and lateral margin of ? 1 mm.

- A poorly differentiated or signet-cell containing adenocarcinoma.

- Lymphatic or vascular invasion (if this feature is unjudgeable due to piecemeal resection, no exclusion is done).

- Tumor budding grade II-III.

- Suspicion of dissemination on investigations as mentioned in the inclusion criteria.

- Patients already receiving anti-tumor treatment for another tumor or a synchronic colorectal cancer.

- Patients in whom a second-look endoscopy would require major and unacceptable effort and / or resources, for instance clinical admission for bowel preparation, long travel, general anesthesia, extremely difficult to reach polypectomy site. Such at the decision of the patient and / or treating physician.

- Patient is planned for trans-anal surgery.

- Patient is not planned for surgery.

- Patient is pregnant.

- Patient does not provide written informed consent or is unable to provide such.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Flexible sigmoidoscopy or colonoscopy
Depending on the localization of the scar of the malignant polyp, either a flexible sigmoidoscopy or colonoscopy will be done to take biopsies from the polypectomy scar.

Locations

Country Name City State
Netherlands Meander Medical Center Amersfoort Utrecht
Netherlands Academical Medical Center, Gastroenterology department Amsterdam Noord-Holland
Netherlands Medical Center Slotervaart Amsterdam Noord-Holland
Netherlands Onze Lieve Vrouwe Gasthuis (Oost & West) Amsterdam Noord-Holland
Netherlands The Netherlands Cancer Institute Antoni van Leeuwenhoekhuis Amsterdam Noord-Holland
Netherlands Gelre Hospitals Apeldoorn Gelderland
Netherlands Medical Center de Veluwe Apeldoorn Gelderland
Netherlands Maasstad Hospital Pantein Beugen Noord-Brabant
Netherlands Amphia Hospital Breda Noord-Brabant
Netherlands IJsselland Hospital Capelle Aan Den IJssel Zuid-Holland
Netherlands Haga Hospital Den Haag Zuid-Holland
Netherlands Deventer Hospital Deventer Overijssel
Netherlands Albert Schweitzer Hospital Dordrecht Zuid-Holland
Netherlands Nij Smellinghe Hospital Drachten Friesland
Netherlands Hospital Gelderse Vallei Ede Gelderland
Netherlands Catharina Hospital Eindhoven Noord-Brabant
Netherlands Rivas Zorggroep Gorinchem Zuid-Holland
Netherlands Groene Hart Hospital Gouda Zuid-Holland
Netherlands Martini Hospital Groningen
Netherlands University Medical Center Groningen Groningen
Netherlands Spaarne Gasthuis Haarlem Noord-Holland
Netherlands Ziekenhuis Groep Twente Hengelo Overijssel
Netherlands Alrijne Hospital Leiden Zuid-Holland
Netherlands Maastricht University Medical Center Maastricht Limburg
Netherlands Sint Antonius Hospital Nieuwegein Utrecht
Netherlands Canisius Wilhelmina Hospital Nijmegen Gelderland
Netherlands Radboud University Medical Center Nijmegen Gelderland
Netherlands Erasmus Medical Center, Gastroenterology department Rotterdam Zuid-Holland
Netherlands Franciscus Gasthuis Rotterdam Zuid-Holland
Netherlands Ikazia Hospital Rotterdam Zuid-Holland
Netherlands Maasstad Hospital Rotterdam Zuid-Holland
Netherlands Vlietland Hospital Schiedam Zuid-Holland
Netherlands Antonius Hospital Sneek-Emmeloord Sneek Friesland
Netherlands Bernhoven Uden Noord-Brabant
Netherlands University Medical Center Utrecht, Gastroenterology department Utrecht
Netherlands Isala Clinics Zwolle Overijssel

Sponsors (5)

Lead Sponsor Collaborator
Dr. Frank ter Borg MD PhD Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Erasmus Medical Center, The Netherlands Cancer Institute, UMC Utrecht

Country where clinical trial is conducted

Netherlands, 

References & Publications (11)

Benizri EI, Bereder JM, Rahili A, Bernard JL, Vanbiervliet G, Filippi J, Hébuterne X, Benchimol D. Additional colectomy after colonoscopic polypectomy for T1 colon cancer: a fine balance between oncologic benefit and operative risk. Int J Colorectal Dis. 2012 Nov;27(11):1473-8. doi: 10.1007/s00384-012-1464-0. Epub 2012 Mar 29. — View Citation

Butte JM, Tang P, Gonen M, Shia J, Schattner M, Nash GM, Temple LK, Weiser MR. Rate of residual disease after complete endoscopic resection of malignant colonic polyp. Dis Colon Rectum. 2012 Feb;55(2):122-7. doi: 10.1097/DCR.0b013e3182336c38. Erratum in: Dis Colon Rectum. 2012 Apr;55(4):498. Nash, Garret M [corrected to Nash, Garrett M]. — View Citation

Cooper GS, Xu F, Barnholtz Sloan JS, Koroukian SM, Schluchter MD. Management of malignant colonic polyps: a population-based analysis of colonoscopic polypectomy versus surgery. Cancer. 2012 Feb 1;118(3):651-9. doi: 10.1002/cncr.26340. Epub 2011 Jul 12. — View Citation

Di Gregorio C, Bonetti LR, de Gaetani C, Pedroni M, Kaleci S, Ponz de Leon M. Clinical outcome of low- and high-risk malignant colorectal polyps: results of a population-based study and meta-analysis of the available literature. Intern Emerg Med. 2014 Mar;9(2):151-60. doi: 10.1007/s11739-012-0772-2. Epub 2012 Mar 27. Review. — View Citation

Ikematsu H, Yoda Y, Matsuda T, Yamaguchi Y, Hotta K, Kobayashi N, Fujii T, Oono Y, Sakamoto T, Nakajima T, Takao M, Shinohara T, Murakami Y, Fujimori T, Kaneko K, Saito Y. Long-term outcomes after resection for submucosal invasive colorectal cancers. Gastroenterology. 2013 Mar;144(3):551-9; quiz e14. doi: 10.1053/j.gastro.2012.12.003. Epub 2012 Dec 8. — View Citation

Kitajima K, Fujimori T, Fujii S, Takeda J, Ohkura Y, Kawamata H, Kumamoto T, Ishiguro S, Kato Y, Shimoda T, Iwashita A, Ajioka Y, Watanabe H, Watanabe T, Muto T, Nagasako K. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol. 2004 Jun;39(6):534-43. — View Citation

Meining A, von Delius S, Eames TM, Popp B, Seib HJ, Schmitt W. Risk factors for unfavorable outcomes after endoscopic removal of submucosal invasive colorectal tumors. Clin Gastroenterol Hepatol. 2011 Jul;9(7):590-4. doi: 10.1016/j.cgh.2011.02.002. Epub 2011 Feb 12. — View Citation

Mitchell PJ, Haboubi NY. The malignant adenoma: when to operate and when to watch. Surg Endosc. 2008 Jul;22(7):1563-9. doi: 10.1007/s00464-008-9850-y. Epub 2008 Mar 25. Review. — View Citation

Netzer P, Forster C, Biral R, Ruchti C, Neuweiler J, Stauffer E, Schönegg R, Maurer C, Hüsler J, Halter F, Schmassmann A. Risk factor assessment of endoscopically removed malignant colorectal polyps. Gut. 1998 Nov;43(5):669-74. — View Citation

Seitz U, Bohnacker S, Seewald S, Thonke F, Brand B, Bräiutigam T, Soehendra N. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum. 2004 Nov;47(11):1789-96; discussion 1796-7. Review. — View Citation

Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K, Matsukuma S, Kanai T, Kurihara H, Ozawa K, Yoshimura K, Bekku S. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004 Aug;127(2):385-94. — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity of biopsies for residual cancer The number of patients with endoscopic biopsies containing adenocarcinoma divided by the number of patients with adenocarcinoma in the resected specimen. up to 1 year
Secondary 90-day mortality after rescue surgery The number of patients that died within 91 day after the operation for presumed residual adenocarcinoma. 91 days from surgery
Secondary The sensitivity of biopsies for residual cancer in the bowel wall The number of patients with endoscopic biopsies containing adenocarcinoma divided by the number of patients with adenocarcinoma in the resected bowel wall (regardless of regional lymph nodes) up to 1 year
Secondary The number of complications (defined according to GCP) after biopsies from the polypectomy scar The number of patients with bleeding or perforation after taking biopsies from the polypectomy scar, requiring at least prolongation of treatment, or admission to hospital, or delay or speeding up of surgery. up to 30 days
Secondary The sensitivity of global endoscopic assessment of polypectomy site for residual cancer at initial and follow-up endoscopy (to take scar biopsies) The number of patients in whom the endoscopic resection initially and/or at follow-up endoscopic was assessed as incomplete and who also have residual cancer in the surgically resected specimen divided by the total number of patients in whom the endoscopic resection was judged to be incomplete. up to 1 year
Secondary The proportion of patients with residual cancer in the resected specimen if malignancy was unsuspected during the endoscopic polypectomy The number of patients in whom the malignancy was initially unsuspected during endoscopic polypectomy and who also have residual cancer in the surgical specimen divided by the total number of patients in whom the malignancy was initially unsuspected during endoscopic polypectomy. up to 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A